(0.16%) 5 139.75 points
(0.17%) 38 508 points
(0.21%) 17 884 points
(-0.66%) $83.30
(1.87%) $1.959
(0.02%) $2 347.60
(0.16%) $27.58
(0.79%) $929.35
(-0.17%) $0.933
(-0.26%) $11.00
(-0.26%) $0.798
(1.04%) $92.83
@ $13.37
発行日: 15 2月 2024 @ 04:08
リターン: 11.41%
前回のシグナル: 2月 14 - 00:35
前回のシグナル:
リターン: 0.00 %
Live Chart Being Loaded With Signals
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States...
Stats | |
---|---|
本日の出来高 | 772 159 |
平均出来高 | 1.34M |
時価総額 | 1.75B |
EPS | $0 ( 2024-03-20 ) |
次の収益日 | ( $0.340 ) 2024-05-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 23.63 |
ATR14 | $0.00800 (0.05%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-08 | Tierney David S | Buy | 25 000 | Common stock, par value $0.001 per share |
2024-04-08 | Tierney David S | Sell | 25 000 | Common stock, par value $0.001 per share |
2024-04-08 | Tierney David S | Buy | 25 000 | Options to purchase common stock |
2024-03-27 | Elsbernd Brian | Sell | 25 000 | Common stock, par value $0.001 per share |
2024-02-15 | Del Carmen Jeffrey | Sell | 10 667 | Restricted Stock Units |
INSIDER POWER |
---|
37.04 |
Last 100 transactions |
Buy: 3 182 900 | Sell: 1 448 545 |
ボリューム 相関
Catalyst Pharmaceuticals 相関
10 最も正の相関 | |
---|---|
PMTS | 0.897 |
KPTI | 0.88 |
AVID | 0.873 |
PRAA | 0.854 |
FCCO | 0.852 |
BNIXU | 0.849 |
PINC | 0.848 |
KTCC | 0.844 |
PARA | 0.843 |
DTEA | 0.838 |
10 最も負の相関 | |
---|---|
CVGI | -0.927 |
CRSP | -0.915 |
NNOX | -0.915 |
POWL | -0.914 |
ADMS | -0.914 |
FTDR | -0.912 |
MDXG | -0.912 |
FLGC | -0.905 |
CNCE | -0.905 |
RESN | -0.904 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Catalyst Pharmaceuticals 相関 - 通貨/商品
Catalyst Pharmaceuticals 財務諸表
Annual | 2023 |
収益: | $398.20M |
総利益: | $313.67M (78.77 %) |
EPS: | $0.670 |
FY | 2023 |
収益: | $398.20M |
総利益: | $313.67M (78.77 %) |
EPS: | $0.670 |
FY | 2022 |
収益: | $214.20M |
総利益: | $179.81M (83.94 %) |
EPS: | $0.800 |
FY | 2021 |
収益: | $140.83M |
総利益: | $118.95M (84.46 %) |
EPS: | $0.380 |
Financial Reports:
No articles found.
Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。